|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||156.75 - 158.64|
|52 Week Range||114.27 - 197.00|
|Beta (3Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.96 (1.88%)|
|1y Target Est||N/A|
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.
Allergan chief executive Brent Saunders disclosed the role of JPMorgan and Wachtell, Lipton, Rosen & Katz asadvisers to the company on its planned sale to AbbVie, not AbbVie chief executive Richard Gonzalez ...
Top advisory shops, including the likes of Goldman Sachs and Morgan Stanley, have long shunned activists for fear of alienating their corporate clients. As a result, shareholder activism has become a lucrative business for banks hoping to cosy up to corporates in search of future business and hefty fees.
Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.
JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie. the $120m paid to Morgan Stanley for advising US agribusiness Monsanto on its $66bn sale to Germany’s Bayer in 2016, according to data from Dealogic. The details of the fee arrangement were disclosed by Allergan this week as it prepares for a shareholder vote on its sale to Chicago-based AbbVie.
Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade. "We did not anticipate revenue coming in the second quarter in a meaningful way," Chief Executive Officer David Moatazedi told Reuters in an interview. Evolus, whose shares rose 1.6% in premarket trading, expects to achieve the number two market position in the next 24 months.
Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations. Jeuveau, a neurotoxin drug to treat forehead wrinkles, was launched on May 15 and competes with Botox, which has grown to dominate the medical aesthetics market since it was launched in 2002. Evolus has rolled out a marketing program called J.E.T (Jeuveau Experience Treatment) that ties up with medical aesthetics clinics to provide new customers with up to three shipments of the treatment for free.
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Growth in sales of anti-wrinkle treatment Botox and dermal filler Juvaderm helped drive Allergan Plc to an earnings beat on Tuesday, but gains were offset by a decline in Restasis and CoolSculpting sales.
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.
Allergan (AGN) delivered earnings and revenue surprises of 0.92% and 3.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Allergan (NYSE: AGN ) reported second-quarter earnings of $4.38 per share, which beat the analyst consensus estimate of $4.34 by 0.92%. This is a 0.9% decrease over earnings of $4.42 per share from the ...
Allergan Plc reported second-quarter earnings on Tuesday that beat Wall Street expectations. The company reported a loss of $1.759 billion, or a loss of $5.37 a share, compared with a loss of $472.5 million, or a loss of $1.39 a share, one year ago. Adjusted EPS was $4.38 a share, topping the FactSet consensus of $4.35 a share. Allergan said it had recorded a pre-tax impairment charge of $1.65 billion in the latest quarter, which included a goodwill impairment of $1.09 billion that the company said was primarily due to delays in in clinical studies and a reduction in the expected value of some R&D projects. Revenue from the latest quarter was $4.09 billion, down slightly from $4.12 billion a year ago, but still ahead of the FactSet consensus of $3.935 billion. Botox sales rose 4.2% to $974 million, while sales of Restasis fell 3.4% to $322.8 million. Revenue from Juvaderm rose 11.3% to $329.3 million. The company raised its full-year revenue guidance to between $15.425 billion and $15.625 billion from between $15.125 billion and $15.425 billion. Shares of Allergan have gained 20.2% in the year to date through Monday, while the S&P 500 has gained 13.5%.
Allergan posted stronger-than-expected second quarter earnings Tuesday, and re-affirmed its full-year profit guidance, after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie in late June.
Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.